Phosphodiesterase Inhibitor Improves Renal Tubulointerstitial Hypoxia of the Diabetic Rat Kidney
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Renal hypoxia is involved in the pathogenesis of diabetic nephropathy. Pentoxifyllin (PTX), a nonselective phosphodiesterase inhibitor, is used to attenuate peripheral vascular diseases. To determine whether PTX can improve renal hypoxia, we investigated its effect in the streptozocin (STZ)-induced diabetic kidney. Methods: PTX (40 mg/kg, PO) was administered to STZ-induced diabetic rats for 8 weeks. To determine tissue hypoxia, we examined hypoxic inducible factor-1α (HIF-1α), heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT-1) levels. We also tested the effect of PTX on HIF-1α in renal tubule cells. Results: PTX reduced the increased protein creatinine ratio in diabetic rats at 8 weeks. HIF-1α, VEGF, and GLUT-1 mRNA expression increased significantly, and the expression of HO-1 also tended to increase in diabetic rats. PTX significantly decreased mRNA expression of HIF-1α and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-1 at 4 weeks. The expression of HIF-1α protein was significantly increased at 4 and 8 weeks in tubules in the diabetic rat kidney. PTX tended to decrease HIF-1α protein expression at 8 weeks. To examine whether PTX had a direct effect on renal tubules, normal rat kidney cells were stimulated with CoCl2 (100 μM), which enhanced HIF-1α mRNA and protein levels under low glucose conditions (5.5 mM). Their expressions were similar even after high glucose (30 mM) treatment. PTX had no effect on HIF-1α expression. Conclusions: PTX attenuates tubular hypoxia in the diabetic kidney.
Abstract
Background/Aims: Renal hypoxia is involved in the pathogenesis of diabetic nephropathy. Pentoxifyllin (PTX), a nonselective phosphodiesterase inhibitor, is used to attenuate peripheral vascular diseases. To determine whether PTX can improve renal hypoxia, we investigated its effect in the streptozocin (STZ)-induced diabetic kidney. Methods: PTX (40 mg/kg, PO) was administered to STZ-induced diabetic rats for 8 weeks. To determine tissue hypoxia, we examined hypoxic inducible factor-1α (HIF-1α), heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT-1) levels. We also tested the effect of PTX on HIF-1α in renal tubule cells. Results: PTX reduced the increased protein creatinine ratio in diabetic rats at 8 weeks. HIF-1α, VEGF, and GLUT-1 mRNA expression increased significantly, and the expression of HO-1 also tended to increase in diabetic rats. PTX significantly decreased mRNA expression of HIF-1α and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-1 at 4 weeks. The expression of HIF-1α protein was significantly increased at 4 and 8 weeks in tubules in the diabetic rat kidney. PTX tended to decrease HIF-1α protein expression at 8 weeks. To examine whether PTX had a direct effect on renal tubules, normal rat kidney cells were stimulated with CoCl2 (100 μM), which enhanced HIF-1α mRNA and protein levels under low glucose conditions (5.5 mM). Their expressions were similar even after high glucose (30 mM) treatment. PTX had no effect on HIF-1α expression. Conclusions: PTX attenuates tubular hypoxia in the diabetic kidney.
참고문헌 (34)
- Fine LG, "Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia", Kidney Int Suppl, 75, pp.S22~S26 (2000)
- Nangaku M, "Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure", J Am Soc Nephrol, 17, pp.17~25 (2006)
- Bohle A, "The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli: functional interpretation of morphologic findings", Klin Wochenschr, 59, pp.1043~1051 (1981)
- Kang DH, "Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1", J Am Soc Nephrol, 12, pp.1434~1447 (2001)
- Ohashi R, "Peritubular capillary injury during the progression of experimental glomerulonephritis in rats", J Am Soc Nephrol, 11, pp.47~56 (2000)
- Palm F, "Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension", Diabetologia, 46, pp.1153~1160 (2003)
- Ries M, "Renal diffusion and BOLD MRI in experimental diabetic nephropathy: blood oxygen level-dependent", J Magn Reson Imaging, 17, pp.104~113 (2003)
- Rosenberger C, "Adaptation to hypoxia in the diabetic rat kidney", Kidney Int, 73, pp.34~42 (2008)
- Epstein FH, "Physiology of renal hypoxia", Ann N Y Acad Sci, 718, pp.72~81 (1994)
- Ratcliffe PJ, "Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression", J Exp Biol, 201, pp.1153~1162 (1998)
- Rosenberger C, "Cellular responses to hypoxia after renal segmental infarction", Kidney Int, 64, pp.874~886 (2003)
- Goy MF, "cGMP: the wayward child of the cyclic nucleotide family", Trends Neurosci, 14, pp.293~299 (1991)
- Nishio Y, "Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte hemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells", Horm Metab Res, 29, pp.491~495 (1997)
- Aoki M, "Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model", Diabetologia, 44, pp.1034~1042 (2001)
- Sanz MJ, "Rolipram inhibits leukocyte- endothelial cell interactions in vivo through P- and E-selectin downregulation", Br J Pharmacol, 135, pp.1872~1881 (2002)
- Boolell M, "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction", Int J Impot Res, 8, pp.47~52 (1996)
- Teixeira MM, "Phosphodiesterase(PDE)4 inhibitors: anti-inflammatory drugs ofthe future?", Trends Pharmacol Sci, 18, pp.164~171 (1997)
- Thangarajah H, "The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues", Proc Natl Acad Sci U S A, 106, pp.13505~13510 (2009)
- Catrina SB, "Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function", Diabetes, 53, pp.3226~3232 (2004)
- Katavetin P, "High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor", hypoxia-responsible element pathway, 2006, pp.17, 1405~1413
- Baines A, "Glucose stimulates O2 consumption, NOS, and Na", H exchange in diabetic rat proximal tubules, 2002, pp.283, F286~F293
- O’Connor PM, "Renal medullary tissue oxygenation is dependent on both cortical and medullary blood f low", Am J Physiol Renal Physiol, 290, pp.F688~F694 (2006)
- Palm F, "Differentiating between effects of streptozotocin per se and subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model", Diabetes Metab Res Rev, 20, pp.452~459 (2004)
- Izuhara Y, "Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering", J Am Soc Nephrol, 16, pp.3631~3641 (2005)
- Ohtomo S, "Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model", Nephrol Dial Transplant, 23, pp.1166~1172 (2008)
- Nangaku M, "A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia", Arterioscler Thromb Vasc Biol, 27, pp.2548~2554 (2007)
- Watanabe D, "Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy", N Engl J Med, 353, pp.782~792 (2005)
- Aragones J, "Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism", Nat Genet, 40, pp.170~180 (2008)
- Lee SC, "Induction of heme oxygenase-1 protects against podocyte apoptosis under diabetic conditions", Kidney Int, 76, pp.838~848 (2009)
- McCormick BB, "The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis", Am J Kidney Dis, 52, pp.454~463 (2008)
- Cheung P, "Milrinone, a selective phosphodiesterase3 inhibitor, stimulates lipolysis, endogenousglucose production, and insulin secretion", Metabolism, 52, pp.1496~1500 (2003)
- Chang SA, "The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus", Korean J Intern Med, 16, pp.87~92 (2001)
- Frampton JE, "Pentoxifylline (oxpentifylline): a review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders", Drugs Aging, 7, pp.480~503 (1995)
- Tanahashi M, "Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs", J Pharmacol Exp Ther, 289, pp.1533~1538 (1999)